BMT Tandem "Scientific" Meeting
Harbor Ballroom ABC (Manchester Grand Hyatt)
Chairs:
Lloyd E. Damon, MD
and
Muzaffar H. Qazilbash, MD
Disclosures:
L. E. Damon,
Sunesis, Research Investigator:
Research Funding
M. H. Qazilbash,
Celgene, research:
Advisory Board
and
Honoraria
Millennium, Research:
Advisory Board
and
Honoraria
Onyx, Research:
Advisory Board
and
Honoraria
Ostuka, Research:
Research Funding
Positive Pre-Allogeneic Hematopoietic Cell Transplantation (alloHCT) PET Scan in Patients with Non-Hodgkin Lymphoma (NHL) Predicts Higher Risk of Relapse but Has No Impact on Survival
Veronika Bachanova, MD, University of Minnesota Medical Center;
Linda J. Burns, MD, National Marrow Donor Program;
Kwang Woo Ahn, PhD, Medical College of Wisconsin;
Jeanette Carreras, MPH, Medical College of Wisconsin;
David G. Maloney, MD, PhD, Fred Hutchinson Cancer Research Center;
Anna Sureda, MD, Institut Català d'Oncologia, Hospital Duran i Reynals;
Sonali M. Smith, MD, University of Chicago;
Mehdi Hamadani, MD, Medical College of Wisconsin
Successful Salvage of High-Risk B-Cell Non-Hodgkin & Hodgkin Lymphoma (NHL/HL) with Double-Unit Cord Blood Transplantation (DCBT) Provides a Platform for Further Optimization
Parastoo Dahi, MD, Memorial Sloan Kettering Cancer Center;
Craig Sauter, MD, Memorial Sloan Kettering Cancer Center;
Sean Devlin, PhD, Memorial Sloan Kettering Cancer Center;
Marissa Lubin, BA, Memorial Sloan Kettering Cancer Center;
Doris M. Ponce, MD, Memorial Sloan Kettering Cancer Center;
Sergio A. Giralt, MD, Memorial Sloan-Kettering Cancer Center;
Guenther Koehne, MD, PhD, Memorial Sloan-Kettering Cancer Center;
Miguel-Angel Perales, MD, Memorial Sloan Kettering Cancer Center;
Andrew D Zelenetz, M.D., Ph.D., Memorial Sloan Kettering Cancer Center;
Craig H. Moskowitz, MD, Memorial Sloan Kettering Cancer Center;
Juliet Barker, MBBS (Hons) FRACP, Memorial Sloan Kettering Cancer Center
Clinical Outcomes of Multiple Myeloma Patients with TP53 Gene Deletion after Autologous Stem Cell Transplantation: The MD Anderson Cancer Center Experience
Sameh Gaballa, MD, The University of Texas MD Anderson Cancer Center;
Rima Saliba, PhD, The University of Texas MD Anderson Cancer Center;
Jonathan E Brammer, MD, The University of Texas MD Anderson Cancer Center;
Gary Lu, MD, The University of Texas MD Anderson Cancer Center;
Nina Shah, MD, The University of Texas MD Anderson Cancer Center;
Qaiser Bashir, MD, The University of Texas MD Anderson Cancer Center;
Simrit Parmar, MD, The University of Texas MD Anderson Cancer Center;
Fabian Bock, MD, The University of Texas MD Anderson Cancer Center;
Chitra Hosing, MD, The University of Texas MD Anderson Cancer Center;
Uday R. Popat, MD, UT MD Anderson Cancer Center;
Ruby Delgado, The University of Texas MD Anderson Cancer Center;
Gabriela Rondon, MD, The University of Texas MD Anderson Cancer Center;
Jatin Shah, The University of Texas MD Anderson Cancer Center;
Elisabet Manasanch, MD, The University of Texas MD Anderson Cancer Center;
Robert Z. Orlowski, MD, UT MD Anderson Cancer Center;
Richard E. Champlin, MD, The University of Texas MD Anderson Cancer Center;
Muzaffar H. Qazilbash, MD, The University of Texas MD Anderson Cancer Center
Haploidentical Stem Cell Transplantation (HAPLO-HSCT) with Busulfan (BUX) Based Reduced Intensity Conditioning (RIC) Regimens and Post-Transplant Cyclophosphamide (PT-CY) As Gvhd Prophylaxis in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL)
Jorge Gayoso, HGU Gregorio Marañón;
Pascual Balsalobre, HGU Gregorio Marañón;
Maria Jesús Pascual, Hospital Carlos Haya;
Cristina Castilla-Llorente, Hospital Morales Messeguer;
Dolores Caballero, Hospital Clínico;
Mi Kwon, HGU Gregorio Marañón;
David Serrano, HGU Gregorio Marañón;
José Luis Piñana, Hospital Clínico;
Pilar Herrera, Hospital Ramón y Cajal;
Christelle Ferrá, ICO Badalona;
Cristina Pascual, HGU Gregorio Marañón;
Inmaculada Heras, Hospital Morales Messeguer;
Pau Montesinos, Hospital U. La Fe;
Eduardo Olavarría, Complejo Hospitalario de Navarra;
Leyre Bento, Hospital Son Espasses;
Ismael Buño, HGU Gregorio Marañón;
José Luis Diez-Martin, HGU Gregorio Marañón
FDG-PET Interpreted By Deauville Criteria Prior to Allogeneic Transplantation Predicts Outcomes in Patients with Relapsed or Refractory Hodgkin Lymphoma
Aleksandr Lazaryan, MD MPH PhD, University of Minnesota Medical Center;
Linda J. Burns, MD, National Marrow Donor Program;
Qing Cao, MS, University of Minnesota;
Kaan Meric, MD, Haydarpasa Numune Education and Research Hospital;
Claudio G. Brunstein, MD, PhD, University of Minnesota Medical Center;
Brian Lee McClune, DO, Univ of Minnesota Div Hem/Onc Transplant;
Mukta Arora, MD, MS, University of Minnesota Medical Center;
Margaret L. MacMillan, MD, MSc, FRCPC, University of Minnesota;
Jerry Froelich, MD, University of Minnesota;
John E. Wagner, MD, University of Minnesota;
Daniel J. Weisdorf, MD, University of Minnesota Medical Center;
Veronika Bachanova, MD, University of Minnesota Medical Center
Impact of Chromosomal Abnormalities in the Recipients of Allogeneic Hematopoietic Stem Cell Transplantation with Adult T-Cell Leukemia / Lymphoma
Nobuaki Nakano, MD, Imamura Bun-in Hospital;
Takahiro Itoyama, M.D., Ph.D., Imamura Bun-in Hospital;
Ayumu Kubota, MD, Imamura Bun-in Hospital;
Mashahito Tokunaga, MD, Imamura Bun-in Hospital;
Mayumi Tokunaga, M.D., Ph.D., Imamura Bun-in Hospital;
Torahiko Makino, M.D., Ph.D., Imamura Bun-in Hospital;
Shogo Takeuchi, MD, Imamura Bun-in Hospital;
Yoshifusa Takatsuka, MD, Imamura Bun-in Hospital;
Atae Utsunomiya, M.D., Ph.D., Imamura Bun-in Hospital
A Randomized Phase III Trial of Busulfan + Melphalan Vs Melphalan Alone for Multiple Myeloma
Muzaffar H. Qazilbash, MD, The University of Texas MD Anderson Cancer Center;
Peter Thall, PhD, UT MD Anderson Cancer Center;
Patricia S Fox, MS, UT MD Anderson Cancer Center;
Partow Kebriaei, MD, The University of Texas MD Anderson Cancer Center;
Qaiser Bashir, MD, The University of Texas MD Anderson Cancer Center;
Nina Shah, MD, The University of Texas MD Anderson Cancer Center;
Krina Patel, MD, The University of Texas MD Anderson Cancer Center;
Borje S. Andersson, MD, PhD, UT M.D. Anderson Cancer Center;
Yago L. Nieto, MD, PhD, UT MD Anderson Cancer Center;
Ben C. Valdez, PhD, UT M.D. Anderson Cancer Center;
Simrit Parmar, MD, The University of Texas MD Anderson Cancer Center;
Gabriela Rondon, MD, The University of Texas MD Anderson Cancer Center;
Ruby Delgado, The University of Texas MD Anderson Cancer Center;
Yvonne Dinh, BS, UT M.D. Anderson Cancer Center;
Chitra Hosing, MD, The University of Texas MD Anderson Cancer Center;
Uday R. Popat, MD, UT MD Anderson Cancer Center;
Pei Lin, MD, UT M.D. Anderson Cancer Center;
Jatin Shah, The University of Texas MD Anderson Cancer Center;
Robert Z. Orlowski, MD, UT MD Anderson Cancer Center;
Richard E. Champlin, MD, The University of Texas MD Anderson Cancer Center
Long-Term Outcomes of Patients with Advanced Mantle Cell Lymphoma Treated with Allogeneic Hematopoietic Cell Transplantation after Nonmyeloablative Conditioning
Jennifer Vaughn, MD, MSPH, Fred Hutchinson Cancer Research Center (FHCRC);
Mohamed L. Sorror, MD, MSc, Fred Hutchinson Cancer Research Center;
Thomas Chauncey, MD, PhD, VA Puget Sound Healthcare System (VAPSHCS);
Michael A. Pulsipher, MD, University of Utah School of Medicine;
Richard T. Maziarz, MD, Oregon Health and Science University;
Michael B Maris, MD, Rocky Mountain BMT;
Parameswaran N. Hari, MD, MS, CIBMTR/Medical College of Wisconsin;
Ginna G. Laport, MD, Stanford University;
Georg-Nikolaus Franke, University of Leipzig;
Edward Agura, MD, Baylor Univeristy Medical Center;
Amelia Langston, MD, Emory University School of Medicine;
Andrew Rezvani, Stanford University;
Rainer F. Storb, MD, University of Washington;
Brenda M. Sandmaier, MD, Fred Hutchinson Cancer Research Center (FHCRC);
David G. Maloney, MD, PhD, Fred Hutchinson Cancer Research Center (FHCRC)
![[Visit Client Website]](images/banner.gif)